Skip to main content

Table 2 Prevalence of analgesic use and change over time

From: Analgesic use in a Norwegian general population: change over time and high-risk use - The Tromsø Study

 

Population

OTC only

Rx only

OTC + Rx

Total

Survey

T5

T6

T5

T6

 

T5

T6

 

T5

T6

 

T5

T6

 

Age (years)

n (%)

n (%)

%

%

OR (95 % CI)a

%

%

OR (95 % CI)a

%

%

OR (95 % CI)a

%

%

OR (95 % CI)a

Women

              

 30–39

408 (10.4)

295 (4.5)

46.3

55.6

1.45 (1.05–1.99)

2.2

1.4

0.75 (0.23–2.48)

10.3

9.2

1.09 (0.63–1.86)

58.8

66.1

1.37 (1.00–1.86)

 40–49

710 (18.1)

1880 (28.6)

44.9

49.3

1.29 (1.07–1.56)

5.2

3.8

0.87 (0.57–1.31)

10.9

13.6

1.41 (1.08–1.84)

61.0

66.6

1.29 (1.08–1.53)

 50–59

637 (16.2)

1245 (18.9)

32.2

43.6

1.68 (1.36–2.07)

6.0

5.1

1.05 (0.68–1.61)

12.7

11.7

1.85 (0.71–4.80)

50.9

60.4

1.49 (1.23–1.79)

 60–69

1187 (30.2)

1987 (30.2)

29.0

31.4

1.11 (0.96–1.29)

7.6

7.1

0.96 (0.74–1.24)

11.2

11.5

1.01 (0.83–1.22)

47.8

50.0

1.06 (0.94–1.21)

 70–79

871 (22.2)

886 (13.5)

23.7

26.1

1.16 (0.94–1.43)

9.5

8.5

0.95 (0.69–1.31)

11.5

14.3

1.25 (1.00–1.56)

44.7

48.9

1.14 (0.96–1.36)

 80+

118 (3.0)

288 (4.4)

25.4

25.7

1.15 (0.68–1.92)

5.9

8.3

1.18 (0.80–1.77)

15.3

13.9

0.98 (0.53–1.82)

46.6

47.9

1.15 (0.76–1.74)

 30–89

3931 (100)

6581 (100)

32.9

38.9

1.26 (1.17–1.36)

6.7

5.7

0.98 (0.84–1.14)

11.5

12.5

1.19 (1.08–1.30)

51.1

57.2

1.21 (1.13–1.30)

 Age–adjustedb

  

36.7

42.9

1.30 (1.20–1.41)

5.5

4.8

0.98 (0.84–1.14)

11.5

11.9

1.20 (1.09–1.32)

53.7

59.6

1.24 (1.15–1.32)

 p, age trend

  

<.001

<.001

 

<.001

<.001

 

.370

.471

 

<.001

<.001

 

Men

              

 30–39

273 (8.7)

211 (3.6)

30.4

39.3

1.58 (1.08–2.30)

1.8

1.9

1.23 (0.32–4.64)

4.4

5.2

1.40 (0.60–3.29)

36.6

46.5

1.55 (1.08–2.22)

 40–49

569 (18.1)

1646 (27.9)

27.2

33.6

1.45 (1.18–1.78)

2.6

3.8

1.69 (0.97–2.95)

3.3

6.7

2.39 (1.45–3.94)

33.2

44.1

1.56 (1.29–1.89)

 50–59

332 (10.6)

1123 (19.0)

18.4

24.0

1.34 (1.01–1.79)

6.3

4.0

0.68 (0.42–1.13)

2.4

5.8

2.63 (1.25–5.51)

27.1

33.8

1.29 (1.01–1.65)

 60–69

1108 (35.2)

1939 (32.9)

14.0

18.4

1.37 (1.13–1.66)

5.7

4.5

0.84 (0.61–1.15)

4.5

5.2

1.19 (0.87–1.63)

24.2

28.1

1.21 (1.04–1.41)

 70–79

769 (24.5)

803 (13.6)

10.4

14.5

1.52 (1.13–2.06)

5.6

6.7

1.31 (0.88–1.94)

4.3

5.6

1.43 (0.91–2.24)

20.3

26.8

1.46 (1.17–1.83)

 80+

94 (3.0)

178 (3.0)

10.6

10.1

0.93 (0.42–2.05)

7.5

5.6

0.75 (0.28–2.05)

1.1

4.5

4.27 (0.53–34.60)

19.2

20.2

1.05 (0.56–1.96)

 30–89

3145 (100)

5900 (100)

17.3

23.7

1.46 (1.32–1.61)

4.9

4.5

1.02 (0.84–1.23)

3.9

5.8

1.59 (1.31–1.92)

26.1

33.9

1.38 (1.27–1.50)

 Age–adjustedb

  

21.3

27.1

1.48 (1.33–1.65)

4.3

3.9

1.03 (0.85–1.24)

3.5

5.7

1.57 (1.29–1.91)

29.1

36.7

1.39 (1.27–1.52)

 p, age trend

  

<.001

<.001

 

.001

.001

 

.727

.127

 

<.001

<.001

 

p, sex

  

<.001

<.001

 

.037

.046

 

<.001

<.001

 

<.001

<.001

 
  1. The proportion of analgesic users last four weeks and odds ratios for use of analgesics in Tromsø 6 compared to Tromsø 5, according to age, sex and prescription category. The Tromsø Study: Tromsø 5 (2001–02, n = 7076) and Tromsø 6 (2007–08, n = 12,481)
  2. OTC “over-the-counter”, non-prescription, Rx prescription, T5 Tromsø 5, T6 Tromsø 6, CI confidence interval, OR odds ratio
  3. aReference category: non-users of both OTC and Rx
  4. bPrevalence estimates age-adjusted with the Norwegian population 01.01.2008 as standard population
Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us